Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Pervasis Therapeutics Successfully Completes Enrollment for Vascugel Phase II Clinical Trials
August 31st, 2007
Pervasis Therapeutics, Inc., a pioneer in regenerative cell-based therapies and devices, announced that it has successfully completed patient recruitment for its two Phase II clinical trials involving the company's first product, Vascugel(TM). The Phase II clinical studies are to evaluate the continued safety of Vascugel(TM) as well as its efficacy in the maintenance of vascular patency after creation of arteriovenous (AV) access grafts and AV fistulae in patients undergoing dialysis for treatment of end-stage renal disease (ESRD). Recent Phase I results for Vascugel(TM) demonstrated that all primary endpoints of the study were achieved, with no significant safety...
Source: Drug Week (2007-08-31)
|
